- LOGIN
- MemberShip
- 2020-10-24 12:47
Dailypharm Korea will be available without login access until the end of December 2019.
Membership login access would be required from February 2020 to access more news and website services.
Membership login access would be required from February 2020 to access more news and website services.
- Company
- Samsung signed manufacturing collaboration with AZ
- by Eo, Yun-Ho Sep 22, 2020 05:47pm
- AstraZeneca and Samsung Biologics announced the signing of a long-term supply agreement. Under this agreement, valued at approximately $330.8 million, Samsung Biologics will provide large-scale commercial manufacturing for drug substance and drug product of AstraZeneca biologics therapeutics. The contract value could grow to $545.6 millio
- Company
- Cyramza+Tarceva shoots for first-line in EGFR NSCLC patients
- by Eo, Yun-Ho Sep 22, 2020 06:27am
- A combined targeted therapy is seeking for healthcare reimbursement as a first-line treatment in patients with non-small cell lung cancer (NSCLC). The pharmaceutical industry source reported Lilly Korea has recently submitted an application to expand reimbursement on a vascular endothelial growth factor (VEGF) receptor 2 antagonist Cyra
- Company
- Ho-jin Choi inaugurated as CEO of Ono Pharma Korea
- by An, Kyung-Jin Sep 22, 2020 06:26am
- Ono Pharma Korea said that it has elected Choi Ho-jin, vice president of Ono Pharma Korea, as its new chief executive officer effective on Oct. 1. Ono Pharma Korea was established in December 2013 as a Korean subsidiary of Ono Pharmaceutical Co., Ltd. in Japan. New CEO Choi has contributed significantly to the local launch and reimbursemen
- Company
- Combination therapy of Mabthera is on the rise
- by Eo, Yun-Ho Sep 22, 2020 06:26am
- In the field of Chronic Lymphocytic Leukemia (CLL), a combination therapy of a new drug and 'Mabthera (Rituximab)' is attracting attention. According to related industries, the combination therapy of 'Imbruvica (Ibrutinib)' and Mabthera recently obtained approval in Europe after the US. The HIRA’s Pharmaceutical Benefits Advisory Committ
- Company
- Korean companies take drug patent strategy to next level
- by Kim, Jin-Gu Sep 22, 2020 06:26am
- The South Korean pharmaceutical companies are evolving their patent strategies. In the first half of the year, the companies set the historic record of registering the most number of patents. Apparently, their number of patents is on par with multinational pharmaceutical companies’. According to Ministry of Food and Drug Safety (MFDS) and K
- Company
- Sales in the outpatient prescription drug market are active
- by Chon, Seung-Hyun Sep 21, 2020 06:13am
- It has been shown that the outpatient prescription drug market has not been hit even with the recent spread of COVID-19) patients. Even though sales activities contracted due to level 2 social distancing, the total prescription drug volume recorded a growth trend last month. According to UBIST, a drug research institute on the 20th, the amoun
- Company
- Lilly's Olumiant, is clinically approved for COVID-19
- by Kim, Jin-Gu Sep 18, 2020 06:30am
- Eli Lilly's autoimmune disease treatment 'Olumiant (Baricitinib)' has begun phase III clinical trial targeting COVID-19 patients in Korea. It is the second clinical trial in Korea related to COVID-19 after Remdesivir by Gilead Science. On the 7th, the MFDS approved a phase III clinical trial plan of Baricitinib (LY3009104) in Lilly Korea f
- Company
- Julien Samson will be relocating to the UK headquarters
- by Eo, Yun-Ho Sep 18, 2020 06:29am
- According to related industries, GSK Korea held a town hall meeting on the 16th, and Julien Samson, announced that his current term of office as the head of the Korean subsidiary will be ended in this November. Julien Samson will be relocating to the UK headquarters in December. The successor to lead the Korean subsidiary was Robert Kempt
- Company
- “APAC countries need NPM in the age of expensive drugs”
- by Eo, Yun-Ho Sep 17, 2020 06:30am
- A pharmaceutical industry expert suggested Asian-Pacific countries should also take novel payment models into account in this age of high-cost drugs. On Sept. 16, the ‘International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Asia Pacific 2020’ hosted a web session on ‘ICER Threshold for Innovative Medicines &8211; Ha
- Company
- Hanmi promotes clinical use of Keytruda & FLX475
- by Sep 17, 2020 06:29am
- Hanmi is entering a phase II clinical trial that uses a combination of CCR4 target oral immuno-cancer drug (FLX475), which is being developed in Korea, and MSD's immuno-cancer drug Keytruda (Pembrolizumab). To this end, Hanmi announced on the 15th that it has signed a contract with MSD to supply Keytruda for clinical cooperation and clinic
